Sherry DuPree - Senior Hemophilia Institutional Account Manager-Southeast BioPharm - Novo Nordisk | LinkedIn
![NOVO NORDISK A S - NVO / Novo-Nordisk A/S 6-K - Current Report of Foreign Issuer - 6-K - 6-K - February 05, 2020 NOVO NORDISK A S - NVO / Novo-Nordisk A/S 6-K - Current Report of Foreign Issuer - 6-K - 6-K - February 05, 2020](https://www.sec.gov/Archives/edgar/data/353278/000162828020001017/novonordiskannualreport2007.jpg)
NOVO NORDISK A S - NVO / Novo-Nordisk A/S 6-K - Current Report of Foreign Issuer - 6-K - 6-K - February 05, 2020
BioPharm Communications - We are delighted when our customers are delighted! Read what Joanna Suydam of Novo Nordisk has to say about working with BioPharm. “BioPharm's sophisticated analytics and targeting capabilities allow
![Novo Nordisk expands biopharm business and enters research collaboration - Nordic Life Science – the leading Nordic life science news service Novo Nordisk expands biopharm business and enters research collaboration - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2018/11/Jesper-Brandgaard-NovoNordisk-900x675.jpg)
Novo Nordisk expands biopharm business and enters research collaboration - Nordic Life Science – the leading Nordic life science news service
![Novo Nordisk expands its biopharm business - Nordic Life Science – the leading Nordic life science news service Novo Nordisk expands its biopharm business - Nordic Life Science – the leading Nordic life science news service](https://nordiclifescience.org/wp-content/public_html/2018/01/NOVO_NORDISK_HQ-exterior-night-lowres2-1170x700.jpg)
Novo Nordisk expands its biopharm business - Nordic Life Science – the leading Nordic life science news service
![Bertrand Delsuc on X: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / X Bertrand Delsuc on X: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / X](https://pbs.twimg.com/media/Elk4WBRWoAIYM-J.jpg:large)
Bertrand Delsuc on X: "Novo Nordisk R&D milestones Q3'20 $NOVO-B semaglutide ph3 initiating next year in NASH $GMAB mim8 ph1/2 in Hemophilia A readout next year https://t.co/wdlY21E8SB" / X
![Blandine Lacroix - Corporate Vice President, Biopharm & Strategy, Novo Nordisk 06/14 by Fairygodboss Radio | Work Blandine Lacroix - Corporate Vice President, Biopharm & Strategy, Novo Nordisk 06/14 by Fairygodboss Radio | Work](https://dasg7xwmldix6.cloudfront.net/episodes/1197477_AWT4fYG0.jpg)